Harpreet Dhaliwal Sells 17,000 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) insider Harpreet Dhaliwal sold 17,000 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total value of $935,000.00. Following the completion of the transaction, the insider directly owned 76,756 shares in the company, valued at approximately $4,221,580. This represents a 18.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte Stock Performance

PCVX opened at $58.89 on Friday. Vaxcyte, Inc. has a fifty-two week low of $29.08 and a fifty-two week high of $65.00. The company has a market capitalization of $8.50 billion, a P/E ratio of -7.72 and a beta of 1.23. The stock has a fifty day moving average of $53.72 and a 200-day moving average of $55.19.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same quarter last year, the company earned ($1.22) earnings per share. On average, equities research analysts predict that Vaxcyte, Inc. will post -7.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on PCVX shares. Wall Street Zen downgraded shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Zacks Research lowered Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Vaxcyte has a consensus rating of “Hold” and an average target price of $86.00.

Vaxcyte News Summary

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Quarterly loss beat expectations: Vaxcyte reported second-quarter 2026 EPS of negative $1.97, better than analysts’ consensus estimate of negative $2.06. However, the loss was wider than the negative $1.22 reported in the year-earlier quarter. Vaxcyte quarterly earnings release
• Positive Sentiment: Multiple clinical catalysts are ahead: Topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial are expected in the fourth quarter of 2026. Results from OPUS-2 and OPUS-3 are expected in the first half of 2027, while infant VAX-31 data are expected by the end of the first half of 2027. Vaxcyte second-quarter business update
• Positive Sentiment: Strong liquidity supports development: Vaxcyte held approximately $2.5 billion in cash, cash equivalents and investments at June 30, 2026. The balance sheet reduces near-term financing concerns as the company advances its late-stage vaccine programs and VAX-A1.
• Neutral Sentiment: Institutional ownership remains high: Several funds, including Royal Bank of Canada, UBS Asset Management and Cetera Investment Advisers, increased their positions recently. Institutional investors and hedge funds collectively own approximately 96.8% of outstanding shares.
• Negative Sentiment: Executives reported stock sales: The CFO, COO and another insider sold a combined 29,250 shares worth roughly $1.6 million. The transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may still weigh modestly on sentiment. Vaxcyte insider selling report
• Negative Sentiment: Losses are expected to continue: Analysts forecast a full-year 2026 loss of approximately $7.91 per share, underscoring Vaxcyte’s dependence on successful clinical execution and future commercialization.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PCVX. Royal Bank of Canada raised its position in shares of Vaxcyte by 115.2% during the first quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock worth $1,113,000 after acquiring an additional 15,774 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Vaxcyte in the 1st quarter valued at about $219,000. Caxton Associates LLP bought a new stake in shares of Vaxcyte during the 1st quarter valued at about $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Vaxcyte by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock worth $19,409,000 after purchasing an additional 41,034 shares during the period. Finally, Cetera Investment Advisers grew its stake in Vaxcyte by 13.8% during the second quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock worth $250,000 after purchasing an additional 932 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.